QR-Code

Structural variation in the glycogen synthase kinase 3β and brain‐derived neurotrophic factor genes in Japanese patients with bipolar disorders

Abstract Background Lithium is the first‐line drug for the treatment of bipolar disorders (BDs); however, not all patients responded. Glycogen synthase kinase (GSK) 3β and brain‐derived neurotrophic factor (BDNF) play a role in the therapeutic action of lithium. Since structural variations were repo...

Ausführliche Beschreibung

Gespeichert in:
Hauptverfasser: Yosuke Suga, Keiichiro Yoshimoto, Shusuke Numata, Shinji Shimodera, Shogo Takamura, Naoto Kamimura, Ken Sawada, Hiromitsu Kazui, Tetsuro Ohmori, Shigeru Morinobu
Format: Artigo
Sprache:Inglês
Veröffentlicht: Wiley 2020-03-01
Schriftenreihe:Neuropsychopharmacology Reports
Schlagworte:
bipolar disorder
brain‐derived neurotrophic factor
copy number variation
glycogen synthase kinase 3®
lithium
Online-Zugang:https://doi.org/10.1002/npr2.12083
Tags: Tag hinzufügen
Keine Tags, Fügen Sie das erste Tag hinzu!

Ähnliche Einträge